Back to Market Feed

Product Information

BIKTARVY 30-120-15 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $136.6429 per EA under NDC 61958250501. Its NADAC has been published 118 times since May 22, 2024.

FDA first approved this application on Feb 7, 2018.

Strength

30; 120; 15 mg/1; mg/1; mg/1

NDC

61958250501

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Effective Date

8/19/2026

Approval Type

New Drug (NDA)

FDA Application

NDA210251

FDA Approved

2/7/2018

On Market Since

10/7/2021

Pharmacological Classes

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Nucleoside Reverse Transcriptase Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
Nucleosides
Nucleosides

Price Statistics

The NADAC for BIKTARVY 30-120-15 MG TABLET has been published 118 times since May 22, 2024, and over the history we have for it it has risen 6.2%. The table below summarizes its recorded NADAC range and movement.

Current price$136.6429 per EA
All-time high$136.7316 (Apr 15, 2026)
All-time low$128.6639 (May 22, 2024)
52-week high$136.7316
52-week low$136.5043
Median price$136.4782
Average price$134.3260
Largest weekly change+5.9% (Jan 15, 2025)
Weeks tracked118
Tracking sinceMay 22, 2024

Price History

1W

+0.0%

1M

+0.0%

3M

-0.0%

6M

-0.0%

1Y

+0.0%

3Y

N/A

5Y

N/A

All

+6.2%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

EPIVIR 10 MG/ML ORAL SOLN
Brand
49702020548•ViiV Healthcare Company
$0.4452
per ML
ZIAGEN 20 MG/ML SOLUTION
Brand
49702022248•ViiV Healthcare Company
$0.5865
per ML
EPIVIR 150 MG TABLET
Brand
49702020318•ViiV Healthcare Company
$6.6144
per EA
IMURAN 50 MG TABLET
Brand
54766059010•Sebela Pharmaceuticals Inc.
$8.8907
per EA
INTELENCE 100 MG TABLET
Brand
59676057001•Janssen Products LP
$10.9213
per EA
EPIVIR 300 MG TABLET
Brand
49702020413•ViiV Healthcare Company
$13.2940
per EA
COMBIVIR TABLET
Brand
49702020218•ViiV Healthcare Company
$14.3948
per EA
EMTRIVA 200 MG CAPSULE
Brand
61958060101•Gilead Sciences, Inc.
$17.4459
per EA
INTELENCE 200 MG TABLET
Brand
59676057101•Janssen Products LP
$24.3032
per EA
VIREAD 300 MG TABLET
Brand
61958040101•Gilead Sciences, Inc.
$40.7283
per EA

Frequently asked questions

What is the NADAC price of BIKTARVY 30-120-15 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for BIKTARVY 30-120-15 MG TABLET, manufactured by Gilead Sciences, Inc., is $136.6429 per EA (NDC 61958250501), effective Aug 19, 2026.

How has the price of BIKTARVY 30-120-15 MG TABLET changed over time?

Over the history we have for it, the NADAC for BIKTARVY 30-120-15 MG TABLET has risen 6.2%. It has been tracked across 118 weekly CMS publications since May 22, 2024.

What are the highest and lowest recorded NADAC prices for BIKTARVY 30-120-15 MG TABLET?

Since May 22, 2024, the NADAC for BIKTARVY 30-120-15 MG TABLET has ranged from a low of $128.6639 (May 22, 2024) to a high of $136.7316 (Apr 15, 2026), with a median of $136.4782 per EA.

Are there cheaper alternatives to BIKTARVY 30-120-15 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of BIKTARVY 30-120-15 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures BIKTARVY 30-120-15 MG TABLET?

BIKTARVY 30-120-15 MG TABLET (NDC 61958250501) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.